Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder

• Status: Completed
• Trial end date: 2007-08-01

Summary

Primary Objective:

• To evaluate the effects of two fixed doses of SSR149415 (250 mg bid and 100 mg bid) on hypothalamic-pituitary-adrenal axis function in patients with major depressive disorder.

Secondary Objectives:

• To evaluate the tolerability and safety of SSR149415 in patients with major depressive disorder.

• To evaluate the efficacy of two fixed doses of SSR149415 compared to placebo in patients with major depressive disorder.

• To evaluate plasma concentrations of SSR149415.

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi
• Treatments: Arginine Vasopressin; Vasopressins